---
title: "CSPC PHARMA's SYH2059 inhalation powder clinical trial approved by the US FDA"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/278261628.md"
description: "CSPC PHARMA announced that the Group's developed chemical drug Class 1 new drug SYH2059 inhalation powder has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. The approved clinical indications include idiopathic pulmonary fibrosis and progressive pulmonary fibrosis"
datetime: "2026-03-08T10:49:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278261628.md)
  - [en](https://longbridge.com/en/news/278261628.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278261628.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278261628.md) | [English](https://longbridge.com/en/news/278261628.md)


# CSPC PHARMA's SYH2059 inhalation powder clinical trial approved by the US FDA

CSPC PHARMA (01093.HK) announced that the Group's developed chemical drug Class 1 new drug SYH2059 inhalation powder has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. The approved clinical indications include idiopathic pulmonary fibrosis and progressive pulmonary fibrosis

### 相關股票

- [CSPC PHARMA (01093.HK)](https://longbridge.com/zh-HK/quote/01093.HK.md)

## 相關資訊與研究

- [CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Highly Selective PDE4B Inhibitor SYH2059 Powder For Inhalation In The U.S](https://longbridge.com/zh-HK/news/278107398.md)
- [CSPC Pharmaceutical says indacaterol acetate and mometasone furoate powder for inhalation obtains clinical trial approval in China](https://longbridge.com/zh-HK/news/277929926.md)
- [CSPC Pharma Gets China Nod for Multiple Drug Trials](https://longbridge.com/zh-HK/news/270994613.md)
- [Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy](https://longbridge.com/zh-HK/news/276056763.md)
- [CSPC Pharma Unit Files Application with HKEX for Proposed H-Share Listing](https://longbridge.com/zh-HK/news/269327436.md)